Equities Analysts Issue Forecasts for ELAN Q4 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – Equities researchers at William Blair raised their Q4 2025 earnings per share (EPS) estimates for Elanco Animal Health in a research report issued to clients and investors on Thursday, August 7th. William Blair analyst B. Vazquez now anticipates that the company will post earnings of $0.15 per share for the quarter, up from their prior forecast of $0.14. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health’s Q1 2026 earnings at $0.35 EPS, Q2 2026 earnings at $0.31 EPS, Q3 2026 earnings at $0.17 EPS and FY2026 earnings at $1.00 EPS.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.30 EPS.

A number of other analysts also recently commented on ELAN. UBS Group raised their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Stifel Nicolaus lifted their price target on Elanco Animal Health from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, July 2nd. Leerink Partnrs upgraded Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 17th. Finally, Leerink Partners upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective for the company in a report on Thursday, July 17th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.33.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $17.10 on Monday. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The firm has a market cap of $8.50 billion, a price-to-earnings ratio of 19.89, a P/E/G ratio of 3.12 and a beta of 1.66. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $17.29. The business has a fifty day simple moving average of $14.39 and a 200 day simple moving average of $12.12.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. LPL Financial LLC increased its holdings in Elanco Animal Health by 15.9% during the 4th quarter. LPL Financial LLC now owns 161,183 shares of the company’s stock worth $1,952,000 after purchasing an additional 22,163 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Elanco Animal Health by 53.5% during the fourth quarter. Envestnet Asset Management Inc. now owns 211,904 shares of the company’s stock worth $2,566,000 after acquiring an additional 73,838 shares in the last quarter. Bank of Montreal Can raised its position in shares of Elanco Animal Health by 6.1% in the fourth quarter. Bank of Montreal Can now owns 441,726 shares of the company’s stock worth $5,349,000 after buying an additional 25,390 shares in the last quarter. Invesco Ltd. raised its position in shares of Elanco Animal Health by 10.6% in the fourth quarter. Invesco Ltd. now owns 536,391 shares of the company’s stock worth $6,496,000 after buying an additional 51,233 shares in the last quarter. Finally, Advisory Services Network LLC raised its position in Elanco Animal Health by 296.6% during the fourth quarter. Advisory Services Network LLC now owns 75,993 shares of the company’s stock valued at $920,000 after purchasing an additional 56,833 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.